Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
JCR Pharmaceuticals Co Ltd
4552JCR Pharmaceuticals Co., Ltd., together with its subsidiaries, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells, imports, and exports medical devices and laboratory instruments; and purchases and sells medical and research equipment. The company has a collaboration agreement with Angelini Pharma for the development of novel biologic therapies; and a. joint research agreement with Modalis Therapeutics Corporation to evaluate the drug delivery technology of the gene therapy to the central nervous system (CNS) assuming CNS diseases as a target. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan. Address: 3-19 Kasuga-cho, Ashiya, Japan, 659-0021
Analytics
Objectif de Cours de WallStreet
134 071.71 JPYRatio C/B
–Rendement du dividende
3.26 %Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 4552
Analyse des dividendes 4552
Croissance des dividendes sur 5 ans
196 %Croissance continue
2 annéesRatio de distribution Moyenne sur 5 ans
43 %Historique des dividendes 4552
Valorisation des titres 4552
financières 4552
Résultats | 2019 | Dynamique |